scispace - formally typeset
Open AccessBook ChapterDOI

Solid Lipid Based Nano-particulate Formulations in Drug Targeting

Reads0
Chats0
TLDR
In this chapter, this chapter has discussed about the SLNs and their different surface modified forms for passive as well as active targeting to different organ such as (colon, breast, lungs, liver, kidney, brain, eyes, etc.) in combating different diseases.
Abstract
Recently, targeted drug delivery systems have gained much more interest for delivering varieties of drugs as well as imaging agents specifically to the targeted disease cells or tissues. These are well known for their increased precision and accuracy in mode of drug delivery along with reduced side effects. Though numerous carriers are being employed for drug targeting, the solid lipid based nanoparticles (SLNs) are preferred over them owing to their ability to encapsulate wide varieties of drugs, biocompatibility, ease of surface modification, scaling up feasibility, and possibilities of both active as well as passive targeting to various organs. Surface of these drug loaded SLNs can be modified by conjugating different ligands to enhance their tissue/organ targeting ability and therapeutic efficacy to much higher extent. In this chapter, we have discussed about the SLNs and their different surface modified forms for passive as well as active targeting to different organ such as (colon, breast, lungs, liver, kidney, brain, eyes, etc.) in combating different diseases.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

TL;DR: In this article , a review of the recent achievements of nano-based technologies for ocular disease diagnosis and treatment is presented, highlighting and updating recent achievements in ocular nanomedicine.
Peer Review

The role of lipid based nanoparticles in brain targeted drug delivery system: An overview

TL;DR: LBNP systems represent one of the most potential colloidal carriers and are preferred over polymeric nanoparticles due to their high stability, excellent targeting ability, increased loading capacity, non-toxicity, low production costs, and ease of preparation.
Journal ArticleDOI

Lipid nanoparticulate drug delivery system for the treatment of hepatic fibrosis

TL;DR: Low therapeutic efficacy and undesirable systemic effect of conventional therapies limit their clinical applications to targethepatic stellate cells in the liver.
References
More filters
Journal ArticleDOI

Nanoparticle-based targeted drug delivery

TL;DR: This article presents an overview of nanotechnology for the biologist and discusses the attributes of the novel XPclad((c)) nanoparticle formulation that has shown efficacy in treating solid tumors, single dose vaccination, and oral delivery of therapeutic proteins.
Journal ArticleDOI

Lipid-based nanoparticles for nucleic acid delivery

TL;DR: This paper focuses on the formulation/assembly of lipid-based nanoparticles (NP) with diameter under 100 nm for delivering nucleic acid in vivo, and examines the major formulation factors that impact the diameter and encapsulation efficiency of DNA-containing NP.
Journal ArticleDOI

Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles

TL;DR: In vivo delivery efficiency and the selectivity of RFP-SLNs were further verified in Sprague–Dawley rats and demonstrated that solid lipid nanoparticles are a promising strategy for the delivery of rifampicin to alveolar macrophages selectively.
Journal ArticleDOI

Nanomedicine in pulmonary delivery.

TL;DR: This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects.
Journal ArticleDOI

Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier

TL;DR: It is shown that iron may cross the bovine brain capillary endothelial cells as a complex with Lf and that the low density lipoprotein receptor-related protein might be involved in this process because its specific antagonist, the receptor-associated protein, inhibits 70% of Lf transport.
Related Papers (5)